中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
2期
50-51
,共2页
瑞舒伐他汀%不稳定型心绞痛%白细胞介素-6(IL-6)%超敏C-反应蛋白(hs-CRP)
瑞舒伐他汀%不穩定型心絞痛%白細胞介素-6(IL-6)%超敏C-反應蛋白(hs-CRP)
서서벌타정%불은정형심교통%백세포개소-6(IL-6)%초민C-반응단백(hs-CRP)
Rosuvastatin%Unstable angina pectoris%Interleukin-6 (IL-6)%High-sensitivity C-reactive protein(hs-CRP)
目的 观察瑞舒伐他汀治疗不稳定型心绞痛(UAP)的临床疗效及IL-6和hs-CRP的变化.方法 选择98例UAP患者随机分为两组,对照组48例给予常规治疗;治疗组50例在对照组治疗的基础上加用瑞舒伐他汀口服.两组疗程均为8周.结果 治疗后治疗组心绞痛发作及心电图改善均显著优于对照组(P均＜0.05).治疗组血清IL-6和hs-CRP显著低于对照组(P＜0.05).治疗组未见明显的不良反应.结论 瑞舒伐他汀治疗UAP能改善心绞痛症状及缺血心电图改变,显著降低血清IL-6和hs-CRP的浓度,且无明显的不良反应.
目的 觀察瑞舒伐他汀治療不穩定型心絞痛(UAP)的臨床療效及IL-6和hs-CRP的變化.方法 選擇98例UAP患者隨機分為兩組,對照組48例給予常規治療;治療組50例在對照組治療的基礎上加用瑞舒伐他汀口服.兩組療程均為8週.結果 治療後治療組心絞痛髮作及心電圖改善均顯著優于對照組(P均＜0.05).治療組血清IL-6和hs-CRP顯著低于對照組(P＜0.05).治療組未見明顯的不良反應.結論 瑞舒伐他汀治療UAP能改善心絞痛癥狀及缺血心電圖改變,顯著降低血清IL-6和hs-CRP的濃度,且無明顯的不良反應.
목적 관찰서서벌타정치료불은정형심교통(UAP)적림상료효급IL-6화hs-CRP적변화.방법 선택98례UAP환자수궤분위량조,대조조48례급여상규치료;치료조50례재대조조치료적기출상가용서서벌타정구복.량조료정균위8주.결과 치료후치료조심교통발작급심전도개선균현저우우대조조(P균＜0.05).치료조혈청IL-6화hs-CRP현저저우대조조(P＜0.05).치료조미견명현적불량반응.결론 서서벌타정치료UAP능개선심교통증상급결혈심전도개변,현저강저혈청IL-6화hs-CRP적농도,차무명현적불량반응.
Objective To observe the clinical effect of Rosuvastatin in the treatment of unstable anginapectoris(UAP) and the clinical efficacy of IL-6 and hs-CRP changes. Methods 98 cases of UAP patients were randomly divided into two groups. 48 cases of control group were were given conventional treatment; 50 cases of treatment group given oral rosuvastatin based on the control group treatment. Both groups were treated for 8weeks. Results After the treatment,the treatment group improvement of angina pectoris and ECG were significantly better than that of the control group(Pl ＜ 0.05). In treatment group, serum IL-6 and hs-CRP were significantly lower than those the control group(P ＜ 0.05 ). Treatment group had no obvious adverse reactions. Conclusion Rosuvastatin treatment of UAP can improve symptoms of angina and ischemic ECG changes, have a significant reduction in serum IL-6 and hs-CRP concentrations,and no significant adverse reactions.
